Mr. Sekhri brings more than 35 years of life sciences industry leadership across all stages of biotech and pharma
NEW YORK, April 1, 2026 /PRNewswire/ -- Petrichor, a leading healthcare and life sciences growth investor, today announced the appointment of Paul J. Sekhri as Operating Partner.
Mr. Sekhri is a highly accomplished executive with over 35 years of leadership experience across the global life sciences industry. His career spans senior operating roles in multinational pharmaceutical companies, venture-backed biotech firms, and top-tier venture capital and private equity organizations.
"We are incredibly fortunate to welcome Paul to the Petrichor family," said Tadd Wessel, Petrichor Founder and Managing Partner. "We have known Paul for years, and we admire his skills as a leader of life sciences companies, both as CEO and as Chairman of the Board. His deep experience and distinguished track record across biotech and big pharma further strengthen our ability to identify and support emerging and leading healthcare innovators in their vitally important work."
Mr. Sekhri currently serves as Chairman, President, and Chief Executive Officer of vTv Therapeutics, Inc. Previously, he was President and CEO of eGenesis, Inc., where he led significant scientific and organizational advancements in xenotransplantation. Earlier roles include President and CEO at Lycera Corporation, a biopharmaceutical company focused on immune-mediated diseases, and Founder, President and CEO at Cerimon Pharmaceuticals, where he built the company from inception and led multiple product development initiatives. Additionally, Mr. Sekhri has held senior business development and strategy roles at Sanofi, Teva Pharmaceutical Industries, Ltd., TPG Biotech, ARIAD Pharmaceuticals, and Novartis AG.
"I have seen firsthand how the Petrichor team helps innovative companies succeed in both transactional and operational settings, and across all key stages of life sciences development," Mr. Sekhri said. "Petrichor has quickly become a uniquely thoughtful investor, leveraging the comprehensive perspective gained over the team's collective decades of experience."
Mr. Sekhri has served on more than 40 public and private company boards. He currently serves on the boards at Veeva Systems Inc., Kayothera Inc., and Deep Genomics, Inc. He is also Chairman of the Board at Resolution Therapeutics Ltd., and Executive Chairman of Violet Therapeutics, Inc. Beyond the life sciences sector, Mr. Sekhri is deeply engaged in the arts. He serves as Chairman of the Board of Young Concert Artists, is a member of the Advisory Council of the New York Philharmonic and previously served on the Board of the Metropolitan Opera.
About Petrichor
Petrichor partners with world-class healthcare managers and businesses to provide customized investment structures and support. Petrichor has completed over 125 investments representing more than $6 billion in invested capital and has held over 50 board seats. Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise. This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies.
For more information on Petrichor, please visit www.petrichorcap.com.
Media Contacts
[email protected]
SOURCE Petrichor
Share this article